Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine news to help you catch up and stay informed.
Bill To Legalize Psychedelics Passes California Senate
The California Senate has passed a bill legalizing the possession of natural psychedelics.
SB 58 legalizes specific amounts of psilocybin, psilocyn, DMT, ibogaine and mescaline. This would be for personal or facilitated use and the “possession, preparation, obtaining, transfer, as specified, or transportation…”
Terran Biosciences Announces New Breakthroughs in the Chemistry of MDMA
Terran Biosciences announces new breakthroughs in the chemistry of MDMA and its enantiomers and analogs, discovers new salts and polymorphs, and publishes PCT application.
Dr. Sam Clark, Terran’s CEO commented, “Developing important new innovations for a classic compound like MDMA was complex, but I am proud of our team for rising to the challenge. We believe that the discovery of these new forms of the empathogens MDMA, MDEA, MBDB, and other analogs, really changes the opportunity set for these molecules, enabling development programs for these new chemical entities. These advances help further fruitful collaboration between investors, industry, and the scientific communities, and makes available a broad set of therapeutic candidates with diverse use profiles customized for individual patient needs.”
Sunstone Therapies Presents Positive Results of Psilocybin Therapy in Cancer Patients
Sunstone Therapies presents data showing positive long-term follow-up results from psilocybin therapy in cancer patients with major depressive disorder (using Compass Pathways’ COMP360)
- 18-month follow-up of patients in phase 2 study shows continued robust clinical response to psilocybin therapy, with sustained response in 64% of patients and two-thirds of patients in remission
- Data presented at ASCO further validates potential of a single dose of psilocybin and simultaneous psychological support for cancer patients with MDD
Small Pharma Expands Intellectual Property Portfolio
“Since the previous IP portfolio update on February 1, 2023, the Company has secured five new granted patents, with three more expected to be granted by May 31, 2023. Additionally, it has received five patent Notices of Allowance.”
These are the main highlights found in Small Pharma’s IP update announced yesterday. The DMT-focused drug development firm is building on its successful Phase 2 results by expanding its already solid intellectual property portfolio.
